{"nctId":"NCT00444951","briefTitle":"Immunogenicity and Safety of Menactra® Vaccine in Adolescents in Saudi Arabia","startDateStruct":{"date":"2007-02"},"conditions":["Neisseria Meningitidis","Meningococcal Infections"],"count":450,"armGroups":[{"label":"Menactra® group","type":"EXPERIMENTAL","interventionNames":["Biological: Menactra®: Meningococcal A, C, Y, and W 135 Polysaccharide Diphtheria Toxoid Conjugate vaccine"]},{"label":"Mencevax® group","type":"EXPERIMENTAL","interventionNames":["Biological: Mencevax®: Group A, C, W135 and Y polysaccharide meningococcal vaccine"]},{"label":"Control group","type":"EXPERIMENTAL","interventionNames":["Biological: Menactra®: Meningococcal A, C, Y, and W 135 Polysaccharide Diphtheria Toxoid Conjugate vaccine"]}],"interventions":[{"name":"Menactra®: Meningococcal A, C, Y, and W 135 Polysaccharide Diphtheria Toxoid Conjugate vaccine","otherNames":["Menactra®"]},{"name":"Mencevax®: Group A, C, W135 and Y polysaccharide meningococcal vaccine","otherNames":["Mencevax®"]},{"name":"Menactra®: Meningococcal A, C, Y, and W 135 Polysaccharide Diphtheria Toxoid Conjugate vaccine","otherNames":["Menactra®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy, as determined by medical history and physical examination.\n* Aged between 16 to 19 years on the day of inclusion (from 16th birthday to 1 day before 20th birthday inclusive).\n* For the Menactra® and Mencevax® groups, one dose of quadrivalent (A, C, Y, W 135) and at least one dose of bivalent (A, C) meningococcal polysaccharide vaccine with no meningococcal vaccine received less than 2 years prior to enrollment.\n* For the Control group, no previous history of any meningococcal vaccination.\n* Informed consent form signed by the parent(s) or other legal representative for subject under 18 years and signed by subject him/herself if subject above 18 years old\n* Able to provide a vaccination log or has available vaccination record in the Health Center\n* Able to attend all scheduled visits and to comply with all trial procedures\n\nExclusion Criteria:\n\n* Serious chronic disease (i.e., cardiac, renal, neurologic, metabolic, rheumatologic, psychiatric, etc.)\n* Known or suspected impairment of immunologic function.\n* Acute medical illness with or without fever within the last 72 hours or an oral temperature ≥ 37.5°C at the time of inclusion.\n* Administration of immune globulin or other blood products within the last three months, injected or oral corticosteroids or other immunomodulatory therapy within six weeks of the study vaccine. Individuals on a tapering dose schedule of oral steroids lasting \\< 7 days may be included in the trial provided that they have not received more than one course within the last two weeks prior to enrollment.\n* Oral or injected antibiotic therapy within the 72 hours prior to vaccination\n* Received any vaccine in the 14-day period prior to study vaccination, or scheduled to receive any vaccination during the 14-day period after study vaccination.\n* Previous history of documented invasive meningococcal disease.\n* Systemic hypersensitivity to any of the vaccines components or history of a life-threatening reaction to the trial vaccines or a vaccine containing the same substances\n* Participation in another clinical trial in the 4 weeks preceding the trial vaccination\n* Planned participation in another clinical trial during the present trial period\n* Any condition, which, in the opinion of the investigator, would pose a health risk to the subject, or interfere with the evaluation of the vaccine.\n* Personal or family history of Guillain Barré syndrome.\n* For female, known or suspected to be pregnant at the time of inclusion","healthyVolunteers":true,"sex":"ALL","minimumAge":"16 Years","maximumAge":"19 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Geometric Mean Titers (GMTs) of Vaccine Serogroups Determined by Serum Bactericidal Activity Using Baby Rabbit Complement (SBA-BR) Pre- and Post-Menactra® Vaccination","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"651.5","spread":null},{"groupId":"OG001","value":"889.7","spread":null},{"groupId":"OG002","value":"441.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4116.3","spread":null},{"groupId":"OG001","value":"3833.4","spread":null},{"groupId":"OG002","value":"6351.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.7","spread":null},{"groupId":"OG001","value":"15.8","spread":null},{"groupId":"OG002","value":"16.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"288.3","spread":null},{"groupId":"OG001","value":"158.6","spread":null},{"groupId":"OG002","value":"993.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.8","spread":null},{"groupId":"OG001","value":"73.4","spread":null},{"groupId":"OG002","value":"16.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2770.1","spread":null},{"groupId":"OG001","value":"1936.3","spread":null},{"groupId":"OG002","value":"4204.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.5","spread":null},{"groupId":"OG001","value":"24.5","spread":null},{"groupId":"OG002","value":"8.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2435.5","spread":null},{"groupId":"OG001","value":"1455.7","spread":null},{"groupId":"OG002","value":"6926.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With At Least a 4-Fold Rise in Titers Determined by Serum Bactericidal Activity Using Baby Rabbit Complement (SBA-BR) Post-Menatcra® Vaccination","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66","spread":null},{"groupId":"OG001","value":"62","spread":null},{"groupId":"OG002","value":"86","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71","spread":null},{"groupId":"OG001","value":"57","spread":null},{"groupId":"OG002","value":"81","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80","spread":null},{"groupId":"OG001","value":"69","spread":null},{"groupId":"OG002","value":"96","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84","spread":null},{"groupId":"OG001","value":"72","spread":null},{"groupId":"OG002","value":"96","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Reporting a Solicited Injection Site or Systemic Reactions Post-vaccination","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88","spread":null},{"groupId":"OG001","value":"71","spread":null},{"groupId":"OG002","value":"98","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85","spread":null},{"groupId":"OG001","value":"66","spread":null},{"groupId":"OG002","value":"95","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"34","spread":null},{"groupId":"OG002","value":"42","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null},{"groupId":"OG001","value":"29","spread":null},{"groupId":"OG002","value":"34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87","spread":null},{"groupId":"OG001","value":"86","spread":null},{"groupId":"OG002","value":"90","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"17","spread":null},{"groupId":"OG002","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66","spread":null},{"groupId":"OG001","value":"64","spread":null},{"groupId":"OG002","value":"60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61","spread":null},{"groupId":"OG001","value":"55","spread":null},{"groupId":"OG002","value":"61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null},{"groupId":"OG001","value":"55","spread":null},{"groupId":"OG002","value":"72","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"10","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":144},"commonTop":["Injection site pain","Headache","Myalgia","Malaise","Injection site erythema"]}}}